Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma.
Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma.
复制标题
DOI：
10.20892/j.issn.2095-3941.2017.0007
复制
发表时间：
2017-05
影响因子：
5.5
通讯作者：
Shams A
中科院分区：
文献类型：
--
作者：
Abdou AG;Asaad N;Kandil M;Shabaan M;Shams A
弥漫性大B细胞淋巴瘤（DLBCL）是一组异质性肿瘤，具有不同的生物学和临床特征，具有不同的临床结局和治疗反应。DLBCL的肿瘤微环境的基质-1特征代表细胞外基质沉积和组织细胞浸润，而基质-2代表可能影响肿瘤进展的血管生成。本研究的目的是通过免疫组织化学方法评估基质-1标记（使用CD 31表达）和基质-2标记（使用CD 31表达）在60例DLBCL中的意义，并最终构建生物预后模型（BPM）。DLBCL中微血管密度（P<0.05）和PCNA表达率（P<0.001）均高于反应性滤泡增生。高微血管密度与脾脏受累（P=0.008）、高有丝分裂计数（P=0.045）和包膜浸润（P=0.035）显著相关。脾脏受累率与CD 45表达的百分比显著相关（P=0.03）。构建BPM显示42例（70%）生物学评分低（0-1），18例（30%）生物学评分高（2-3）。与高分病例相比，低BPM病例显示脾脏受累的概率较低（P=0.04），对治疗的完全应答率较高（P=0.08）。 DLBCL微环境可以调节肿瘤进展行为，因为血管生成和CD 14阳性基质细胞通过与脾脏受累和包膜浸润相关而促进播散。生物学预后模型，包括改良的BPM，它考虑了DLBCL的细胞来源和基质信号通路，可以确定DLBCL的进展和对治疗的反应。
: Diffuse Large B Cell Lymphoma (DLBCL) is a heterogeneous group of tumors with different biological and clinical characteristics that have diverse clinical outcomes and response to therapy. Stromal-1 signature of tumor microenvironment of DLBCL represents extracellular matrix deposition and histiocytic infiltrate, whereas stromal-2 represents angiogenesis that could affect tumor progression. : The aim of the present study is to assess the significance of stromal-1 signature using SPARC-1 and stromal-2 signature using CD31 expression and then finally to construct biologic prognostic model (BPM) in 60 cases of DLBCL via immunohistochemistry. : Microvessel density (P<0.05) and SPARC percentage of expression (P<0.001) were higher in DLBCL, including germinal and nongerminal cases, compared with reactive follicular hyperplasia. High microvessel density was significantly associated with splenic involvement (P=0.008), high mitotic count (P=0.045), and presence of capsular invasion (P=0.035). Percentage of SPARC expression was significantly associated with splenic involvement (P=0.03). Constructing BPM showed that 42 cases (70%) were of low biologic score (0–1) and 18 cases (30%) were of high biologic score (2–3). Low BPM cases showed less probability for splenic involvement (P=0.04) and a higher rate of complete response to therapy compared with high score cases (P=0.08). : The DLBCL microenvironment could modulate tumor progression behavior since angiogenesis and SPARC positive stromal cells promote dissemination by association with spleen involvement and capsular invasion. Biologic prognostic models, including modified BPM, which considered cell origin of DLBCL and stromal signature pathways, could determine DLBCL progression and response to therapy.